KALA
KALA BIO, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.17
−5.48%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +74.6%
- EBIT
- +49.0%
- EPS
- +9.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +93.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- +28.0%
- EBIT
- +3.1%
- Net income
- +29.9%
- EPS
- +67.4%
- Free cash flow
- -8.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026